{"slug":"tirzepatide-postherpetic","verification":{"valid":true,"entries":2,"head":"9bc5c97a7b5f4f9066a211cf1ce21f704de6abff22a9bffd43a6791357fa09ac"},"energy":{"passes":2,"tokens_in":22676,"tokens_out":3239,"tokens_total":25915,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"9bc5c97a7b5f4f9066a211cf1ce21f704de6abff22a9bffd43a6791357fa09ac"},"provenance":[{"ts":"2026-06-29T22:41:10.732Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Postherpetic\nSlug: tirzepatide-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condit","response":"{\n  \"slug\": \"tirzepatide-postherpetic\",\n  \"title\": \"Tirzepatide for Postherpetic Neuralgia: Weight Loss, Mechanical Load, and Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia develops after an outbreak of shingles (herpes zoster). The varicella-zoster virus damages sensory nerves. This leaves some people with persistent burning, stabbing, or allodynia pain that lasts months or years.\\n\\nDegeneration layers include peripheral nerve fiber loss, dorsal root ganglion changes, and central nervous system sensitization. Inflammation lingers in affected dermatomes. Pain pathways become amplified even without ongoing tissue injury.\\n\\nIf body weight is elevated, an additional mechanical layer can appear. Excess mass increases compressive forces on the spine and joints. This does not cause the neuralgia but can intensify pain signals when nerves already sit in a heightened state. Standard care focuses on symptom suppression with anticonvulsants, antidepressants, or topicals. These do not target the underlying nerve repair or load factors.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: The same mechanical overload pattern seen in other GLP-1 contexts appears when body weight remains high. Each extra pound adds roughly four pounds of compressive force across lumbar structures during daily movement. Nerves already sensitized by prior viral damage receive repeated mechanical irritation.\\n\\n2. What Tirzepatide is studied to do: Tirzepatide activates GLP-1 and GIP receptors. Large human trials document substantial weight reduction. Average losses exceed 15 percent of starting body weight over 72 weeks. This directly lowers total mass pressing on the spine and surrounding tissues.\\n\\n3. Therefore for you: If elevated body weight forms part of your pain picture, Tirzepatide is discussed because it addresses the metabolic-load layer. Reduced mass lowers mechanical stress on already compromised nerves. The approach targets a repair pathway ","tokens_in":22676,"tokens_out":3239,"cost":0,"prev":"genesis","hash":"2945150c6ef782cb7fa27decd7f4893f9a7977e65fc38e0c7621226643d6cec5"},{"ts":"2026-07-17T02:43:19.007Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-postherpetic","response":"29 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2945150c6ef782cb7fa27decd7f4893f9a7977e65fc38e0c7621226643d6cec5","hash":"9bc5c97a7b5f4f9066a211cf1ce21f704de6abff22a9bffd43a6791357fa09ac"}]}